Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) dropped -4.63% and closed the trade at $ 5.56. The company recorded a trading capacity of 9.8 million shares above its three months average daily volume of 2.8 million shares. During the last trade, shares reached to high price of $5.90 and touched the low price of $5.45. The stock’s 50-day moving average is noted at $4.71 and its 200-day moving average is stands at $3.74.
Additionally, the company has EPS of -1.21. The company has market capitalization of $997.72M.
Currently Synergy Pharmaceuticals, Inc. (SGYP) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “4″ Analysts”. “0” rated “Sell” for the company. “1” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $9.90 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $15.00 however minimum price target advised by analysts is $4.00. The Median price target for the stock is measured at $11.00.
Presently, Analysts decided consensus EPS estimate of $-0.19 for present quarter and one month ago projected EPS estimate was at $-0.19. If we take a look at back 3 month ago, consensus EPS estimate was $-0.18.
A current consensus EPS estimate for next quarter is at $-0.18 and 3 month ago EPS forecast was $-0.17. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.18.
For current fiscal year, most recent EPS estimate is set at $-0.96 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.92. During period one month ago, consensus EPS forecast was decided at $-0.95.
A current consensus EPS projection for next fiscal year is observed at $-0.44 and one month ago consensus EPS forecast was at $-0.45. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.53 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 4 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 1 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 1 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.